Evaxion Biotech A/S (NASDAQ:EVAX) Given Buy Rating at HC Wainwright

Posted by Jessica Moore on Feb 22nd, 2025

Evaxion Biotech A/S (NASDAQ:EVAX – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They currently have a $14.00 target price on the stock. HC Wainwright’s target price would indicate a potential upside of 453.36% from the company’s current price.

Separately, Lake Street Capital lowered their price target on Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, February 4th.

Read Our Latest Research Report on Evaxion Biotech A/S

Evaxion Biotech A/S Stock Down 4.9 %

Shares of EVAX opened at $2.53 on Thursday. The company has a market cap of $2.97 million, a PE ratio of -1.74 and a beta of -0.28. The business has a fifty day moving average of $3.65 and a 200 day moving average of $9.60. Evaxion Biotech A/S has a 52-week low of $2.22 and a 52-week high of $22.05. The company has a quick ratio of 2.80, a current ratio of 1.00 and a debt-to-equity ratio of 7.99.

Institutional Trading of Evaxion Biotech A/S

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. Catalina Capital Group LLC bought a new position in Evaxion Biotech A/S (NASDAQ:EVAX – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 34,864 shares of the company’s stock, valued at approximately $29,000. Catalina Capital Group LLC owned 2.98% of Evaxion Biotech A/S as of its most recent SEC filing. 11.04% of the stock is owned by institutional investors.

About Evaxion Biotech A/S

(Get Free Report)

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.